Regeneron Pharmaceuticals, Inc. (REGN): Price and Financial Metrics


Regeneron Pharmaceuticals, Inc. (REGN): $589.60

-2.55 (-0.43%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add REGN to Watchlist
Sign Up

Industry: Biotech


Ranked

of 491

in industry

REGN POWR Grades


  • REGN scores best on the Value dimension, with a Value rank ahead of 94.17% of US stocks.
  • REGN's strongest trending metric is Momentum; it's been moving down over the last 52 weeks.
  • REGN ranks lowest in Momentum; there it ranks in the 9th percentile.

REGN Stock Summary

  • REGN has a market capitalization of $63,333,627,675 -- more than approximately 95.71% of US stocks.
  • REGN's went public 30.59 years ago, making it older than 83.47% of listed US stocks we're tracking.
  • As for revenue growth, note that REGN's revenue has grown 54.84% over the past 12 months; that beats the revenue growth of 87.57% of US companies in our set.
  • Stocks that are quantitatively similar to REGN, based on their financial statements, market capitalization, and price volatility, are LRCX, VRTX, MU, CDNS, and SNPS.
  • Visit REGN's SEC page to see the company's official filings. To visit the company's web site, go to www.regeneron.com.

REGN Valuation Summary

  • In comparison to the median Healthcare stock, REGN's price/sales ratio is 48.9% lower, now standing at 5.8.
  • REGN's price/sales ratio has moved down 24.1 over the prior 243 months.
  • Over the past 243 months, REGN's EV/EBIT ratio has gone up 38.2.

Below are key valuation metrics over time for REGN.

Stock Date P/S P/B P/E EV/EBIT
REGN 2021-08-31 5.8 4.8 11.6 10.0
REGN 2021-08-30 5.8 4.8 11.7 10.0
REGN 2021-08-27 5.7 4.7 11.4 9.8
REGN 2021-08-26 5.7 4.7 11.5 9.8
REGN 2021-08-25 5.8 4.7 11.5 9.9
REGN 2021-08-24 5.8 4.7 11.5 9.9

REGN Growth Metrics

  • Its year over year net cashflow from operations growth rate is now at 16.03%.
  • The year over year price growth rate now stands at -13.18%.
  • The 3 year cash and equivalents growth rate now stands at 182.76%.
Over the past 15 months, REGN's revenue has gone up $4,404,300,000.

The table below shows REGN's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-06-30 12,384.1 2,271.9 6,205.4
2021-03-31 9,197.6 2,588.6 4,003.8
2020-12-31 8,497.1 2,618.1 3,513.2
2020-09-30 8,243.7 2,174.5 3,156
2020-06-30 7,998.1 2,986.1 2,983.5
2020-03-31 7,979.8 2,231 2,279.3

REGN's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • REGN has a Quality Grade of B, ranking ahead of 86.65% of graded US stocks.
  • REGN's asset turnover comes in at 0.683 -- ranking 43rd of 680 Pharmaceutical Products stocks.
  • JAZZ, AGLE, and VERU are the stocks whose asset turnover ratios are most correlated with REGN.

The table below shows REGN's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.683 0.868 0.456
2021-03-31 0.562 0.868 0.315
2020-12-31 0.536 0.868 0.292
2020-09-30 0.540 0.880 0.283
2020-06-30 0.543 0.882 0.282
2020-03-31 0.553 0.897 0.221

REGN Price Target

For more insight on analysts targets of REGN, see our REGN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $683.25 Average Broker Recommendation 1.52 (Moderate Buy)

REGN Stock Price Chart Interactive Chart >

Price chart for REGN

REGN Price/Volume Stats

Current price $589.60 52-week high $686.62
Prev. close $592.15 52-week low $441.00
Day low $587.70 Volume 658,100
Day high $594.09 Avg. volume 857,344
50-day MA $616.79 Dividend yield N/A
200-day MA $542.77 Market Cap 63.06B

Regeneron Pharmaceuticals, Inc. (REGN) Company Bio


Regeneron Pharmaceuticals is a leading science-based biopharmaceutical company based in Tarrytown, New York that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron commercializes medicines for eye diseases, high LDL-cholesterol and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including oncology, rheumatoid arthritis, asthma, and atopic dermatitis. The company was founded in 1988 and is based in Tarrytown, New York.


REGN Latest News Stream


Event/Time News Detail
Loading, please wait...

REGN Latest Social Stream


Loading social stream, please wait...

View Full REGN Social Stream

Latest REGN News From Around the Web

Below are the latest news stories about Regeneron Pharmaceuticals Inc that investors may wish to consider to help them evaluate REGN as an investment opportunity.

Regeneron (REGN) Stock Moves -0.43%: What You Should Know

Regeneron (REGN) closed at $589.60 in the latest trading session, marking a -0.43% move from the prior day.

Yahoo | October 27, 2021

Biotech Stock Roundup: BMY's Q3 Earnings Beat, MRNA's Vaccine Updates & More

Earnings and other updates from bigwigs like Bristol Myers (BMY) and Moderna (MRNA) have been the biotech sector's few key highlights during the past week.

Yahoo | October 27, 2021

Bristol-Myers (BMY) Beats on Q3 Earnings & Sales, Tweaks View

Bristol-Myers (BMY) beats on earnings and sales in the third quarter on the back of Revlimid, Eliquis, and Opdivo.

Yahoo | October 27, 2021

Macular Edema Treatment Market to Garner Massive Recognition in the Years to Come | Novartis International AG, F. Hoffmann-La Roche Ltd, Regeneron Pharmaceuticals, Inc.

Coherent Market Insights has recently updated its massive report catalog by adding a fresh study titled "Global Macular Edema Treatment Market Industry Analysis, Size, Share, Growth, Trends, & Forecast 2021 2027". This business intelligence study encapsulates vital details

OpenPR | October 26, 2021

Tri Locum Partners LP Buys 10,922 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Tri Locum Partners LP boosted its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 16.9% during the 2nd quarter, HoldingsChannel reports. The institutional investor owned 75,627 shares of the biopharmaceutical companys stock after purchasing an additional 10,922 shares during the quarter. Regeneron Pharmaceuticals comprises 13.8% of Tri Locum Partners LPs portfolio, making the stock []

Dakota Financial News | October 26, 2021

Read More 'REGN' Stories Here

REGN Price Returns

1-mo -2.55%
3-mo 2.61%
6-mo 22.50%
1-year 3.98%
3-year 75.38%
5-year 65.70%
YTD 22.04%
2020 28.66%
2019 0.53%
2018 -0.65%
2017 2.42%
2016 -32.38%

Continue Researching REGN

Want to see what other sources are saying about Regeneron Pharmaceuticals Inc's financials and stock price? Try the links below:

Regeneron Pharmaceuticals Inc (REGN) Stock Price | Nasdaq
Regeneron Pharmaceuticals Inc (REGN) Stock Quote, History and News - Yahoo Finance
Regeneron Pharmaceuticals Inc (REGN) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.9988 seconds.